



Substitute for form 1449/PTO				Complete if Known	
<b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	1	of	2	Attorney Docket Number	1488.1000000/HCC/LMB

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
PL	US10	5,652,225	07/29/1997	Isner	
	US11	5,661,133	08/26/1997	Leiden and Barr	
	US12	5,693,622	12/02/1997	Wolff <i>et al.</i>	
	US13	5,792,453	08/11/1998	Hammond <i>et al.</i>	
	US14	6,121,246	09/19/2000	Isner	
	US15	6,361,946 B1	03/26/2002	Alitalo and Joukov	
	US16	6,451,764 B1	09/17/2002	Lee and Wood	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
PL	FP8	EP 0 186 084 A2	07/02/1986	Merck & Co. Inc.		
	FP9	JP 64-38100 A	02/08/1989	Toray Ind. Inc.		Abs
	FP10	JP 2-117698 A	05/02/1990	Ajinomoto KK and Toray Ind. Inc.		Abs
	FP11	EP 0 399 816 A1	11/28/1990	Merck & Co. Inc.		
	FP12	WO 94/11506 A1	05/26/1994	Arch Development Corporation		
	FP13	WO 00/45835 A1	08/10/2000	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		
	FP14	WO 02/11769 A1	02/14/2002	Human Genome Sciences, Inc. and Coleman		
	FP15	WO 02/083704 A1	10/24/2002	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		

Examiner Signature	<i>Deitel</i>	Date Considered	4.4.06
--------------------	---------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

504217 1.DOC

Examiner Signature	<i>[Signature]</i>	Date Considered	4.4.06
-----------------------	--------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 2005, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>EIGHTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.100000O/HCC/LMB
Sheet	1	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PK	NPL1	Altshuler, D., <i>et al.</i> , "Taurine promotes the differentiation of a vertebrate retinal cell type in vitro," <i>Development</i> 119:1317-1328, The Company of Biologists Limited (December 1993)	
	NPL2	Better, M., <i>et al.</i> , "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," <i>Science</i> 240:1041-1043, American Association for the Advancement of Science (1988)	
	NPL3	Böcker-Meffert, S., <i>et al.</i> , "Erythropoietin and VEGF Promote Neural Outgrowth from Retinal Explants in Postnatal Rats," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:2021-2026, Association for Research in Vision and Ophthalmology (June 2002)	
	NPL4	Colwell, D.E., <i>et al.</i> , "Method for Generating a High Frequency of Hybridomas Producing Monoclonal IgA Antibodies," <i>Meth. Enzymol.</i> 121:42-51, Academic Press, Inc. (1986)	
	NPL5	Danis, R.P., <i>et al.</i> , "Anti-angiogenic therapy of proliferative diabetic retinopathy," <i>Exp. Opin. Pharma.</i> 2:395-407, Ashley Publications Ltd. (March 2001)	
	NPL6	Enholm, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," <i>Trends Cardiovasc. Med.</i> 8:292-297, Elsevier Science Inc. (October 1998)	
	NPL7	Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of angiogenesis," <i>Recent Prog. Hormone Res.</i> 55:15-36, The Endocrine Society (March 2000)	
	NPL8	Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 18:299-339, Begell House, Inc. (August 2001)	
	NPL9	Hannink, M., <i>et al.</i> , "Deletions in the C-Terminal Coding Region of the v-sis Gene: Dimerization Is Required for Transformation," <i>Molec. Cell. Biol.</i> 6:1304-1314, American Society for Microbiology (1986)	
	NPL10	Hirai, M., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/vVEGF-2) in Postmenopausal Uterine Endometrial Carcinoma," <i>Gynecol. Oncol.</i> 80:181-188, Academic Press (February 2001)	

491805v1

Examiner Signature		Date Considered	4.4.06
-----------------------	--	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>EIGHTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	2	of	4	Attorney Docket Number	1488.100000O/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
PL	NPL11	Houck, K.A., <i>et al.</i> , "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," <i>Molec. Endocrinol.</i> 5:1806-1814, Williams & Wilkins (1991)	
	NPL12	Joosten, V., "The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi," <i>Microbial Cell Factories</i> 2:1-15, BioMed Central (January 2003)	
	NPL13	Kelley, M.W., <i>et al.</i> , "Regulation of Proliferation and Photoreceptor Differentiation in Fetal Human Retinal Cell Cultures," <i>Invest. Ophthalmol. Vis. Sci.</i> 36:1280-1289, Association for Research in Vision and Ophthalmology (June 1995)	
	NPL14	Longo, R., <i>et al.</i> , "Anti-angiogenic therapy: Rationale, challenges and clinical studies," <i>Angiogenesis</i> 5:237-256, Kluwer Academic Publishers (December 2002)	
	NPL15	Ngo, J.T., <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr., K. and Le Grand, S., eds., Birkhäuser, Boston, MA, pp. 491-495 (January 1994)	
	NPL16	Rudikoff, S., <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> 79:1979-1983, National Academy of Sciences (1982)	
	NPL17	Schlaeppli, J.-M., <i>et al.</i> , "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor," <i>J. Cancer Res. Clin. Oncol.</i> 125:336-342, Springer-Verlag (May 1999)	
	NPL18	Schratzberger, P., <i>et al.</i> , "Reversal of experimental diabetic neuropathy by VEGF gene transfer," <i>J. Clin. Invest.</i> 107:1083-1092, American Societies for Clinical Investigation (May 2001)	
	NPL19	Schulz-Key, S., <i>et al.</i> , "Ciliary Neurotrophic Factor as a Transient Negative Regulator of Rod Development in Rat Retina," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:3099-3108, Association for Research in Vision and Ophthalmology (September 2002)	
✓	NPL20	Seigel, G.M., "The golden age of retinal cell culture," <i>Molec. Vis.</i> 5:4, Molecular Vision (April 1999)	

491805v1

Examiner Signature		Date Considered	4.4.06
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>EIGHTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	3	of	4	Attorney Docket Number	1488.100000O/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
<i>pl</i>	NPL21	Skerra, A. and Pluckthun, A., "Assembly of a Functional Immunoglobulin F <sub>v</sub> Fragment in <i>Escherichia coli</i> ," <i>Science</i> 240:1038-1041, American Association for the Advancement of Science (1988)	
	NPL22	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Harwood Academic Publishers (March 1999)	
	NPL23	Vale, P.R., <i>et al.</i> , "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1(VEGF2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation Suppl.</i> 100:I.22, Abstract No. 109, American Heart Association Inc. (November 1999)	
	NPL24	Vale, P.R., <i>et al.</i> , "Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial Ischemia," <i>Circulation</i> 103:2138-2143, American Heart Association Inc. (May 2001)	
	NPL25	van der Flier, M., <i>et al.</i> , "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis," <i>J. Neuroimmunol.</i> 160:170-177, Elsevier B.V. (March 2005)	
	NPL26	Verma, I.M. and Somia, N., "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242, Macmillan Publishers Ltd. (September 1997)	
	NPL27	Walsh, D.A., "Angiogenesis and arthritis," <i>Rheumatology</i> 38:103-112, British Society for Rheumatology (February 1999)	
	NPL28	Winkler, K., <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> 165:4505-4514, The American Association of Immunologists (October 2000)	
	NPL29	NCBI Entrez, Accession No. AF010302, Mandriota S.J. and Pepper, M.S. (first available July 16, 1997)	
	NPL30	NCBI Entrez, Accession No. S08167, Paulsson, G. <i>et al.</i> (first available April 23, 1993)	

491805v1

Examiner Signature	<i>[Signature]</i>	Date Considered	4.4.06
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995 (39 CFR 101.118), persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	09/935,726
		Filing Date	August 24, 2001
		First Named Inventor	Hu, Jing-Shan
		Art Unit	1647
		Examiner Name	Landsman, Robert S.
		Attorney Docket Number	1488.1000000/HCC/LMB
Sheet	1	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>ML</i>	NPL32	Borg, J.-P., <i>et al.</i> , "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," <i>Oncogene</i> 10:973-984, Stockton Press (March 1995)	
	NPL33	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-01, Abstract (January 1994)	
	NPL34	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-02, Abstract (January 1995)	
	NPL35	Choi, I.H., <i>et al.</i> , "Angiogenesis and Mineralization During Distraction Osteogenesis," <i>J. Korean Med. Sci.</i> 17:435-447, The Korean Academy of Medical Sciences (August 2002)	
	NPL36	Copy of Declaration of Dr. Kari Alitalo, In re of: U.S. Application No. 08/585,895, Alitalo <i>et al.</i> , filed January 12, 1996, submitted November 26, 1997	
	NPL37	Dias, S., <i>et al.</i> , "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," <i>Blood</i> 99:2179-2184, The American Society of Hematology (March 2002)	
	NPL38	English language abstract of JP 64-38100 A, cited as document FP9 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912	
	NPL39	English language abstract of JP 2-117698 A, cited as document FP10 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024	
	NPL40	Fan, T.-P.D., <i>et al.</i> , "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmacol. Sci.</i> 16:57-66, Elsevier Science Ltd. (February 1995)	
	NPL41	Isner, J.M., <i>et al.</i> , "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> 91:2687-2692, American Heart Association, Inc. (June 1995)	

Examiner Signature	<i>[Signature]</i>	Date Considered	4.4.06
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.100000O/HCC/LMB
Sheet	2	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T <sup>2</sup>
BL	NPL42	Isner, J.M. and Feldman, L.J., "Gene therapy for arterial disease," <i>Lancet</i> 344:1653-1654, The Lancet Ltd. (December 1994)		
	NPL43	Isner, J.M., <i>et al.</i> , "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth Factor," <i>J. Cell. Biochem. (Suppl. 21A)</i> :378, Abstract C6-215, Wiley-Liss (March-April 1995)		
	NPL44	Isner, J.M., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL53354-01, Abstract (March 1995)		
	NPL45	Kubo, H., <i>et al.</i> , "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea," <i>Proc. Natl. Acad. Sci.</i> 99:8868-8873, The National Academy of Sciences (June 2002)		
	NPL46	Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell Differentiation <i>in Vitro</i> by Fibroblast-Derived Soluble Factors," <i>Exp. Cell Res.</i> 215:310-318, Academic Press, Inc. (December 1994)		
	NPL47	Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," <i>J. Cell. Physiol.</i> 151:549-554, Wiley-Liss, Inc. (1992)		
	NPL48	Mesri, E.A., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice," <i>Circulation Res.</i> 76:161-167, American Heart Association, Inc. (February 1995)		
	NPL49	Mühlhauser, J., <i>et al.</i> , "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," <i>Circulation</i> 88:1-475, Abstract No. 2558, American Heart Association (October 1993)		
	NPL50	Mühlhauser, J., <i>et al.</i> , "VEGF <sub>165</sub> Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," <i>Circulation Res.</i> 77:1077-1086, American Heart Association, Inc. (December 1995)		
	NPL51	Oikawa, T., <i>et al.</i> , "Three Isoforms of Platelet-Derived Growth Factors All Have the Capability to Induce Angiogenesis <i>In Vivo</i> ," <i>Biol. Pharm. Bull.</i> 17:1686-1688, (December 1994)		

Examiner Signature		Date Considered	4.4.06
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	09/935,726
		Filing Date	August 24, 2001
		First Named Inventor	Hu, Jing-Shan
		Art Unit	1647
		Examiner Name	Landsman, Robert S.
		Attorney Docket Number	1488.100000O/HCC/LMB
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
ML	NPL52	Pajusola, K., <i>et al.</i> , "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <i>Oncogene</i> 9:3545-3555, Macmillan Press Ltd. (December 1994)	
	NPL53	Pepper, M.S., <i>et al.</i> , "In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells," <i>Exp. Cell Res.</i> 210:298-305, Academic Press, Inc. (January 1994)	
	NPL54	Plate, K.H., "From angiogenesis to lymphangiogenesis," <i>Nat. Med.</i> 7:151-152, Nature America, Inc. (February 2001)	
	NPL55	Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and treatment of diabetic retinopathy," <i>Exp. Clin. Endocrinol. Diabetes</i> 109(Suppl. 2):S438-S450, J.A. Barth Verlag (2001)	
	NPL56	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Taylor & Francis (1999)	
	NPL57	Symes, J.F. and Sniderman, A.D., "Angiogenesis: potential therapy for ischaemic disease," <i>Curr. Opin. Lipidol.</i> 5:305-312, Current Science Ltd. (August 1994)	
	NPL58	Takeshita, S., <i>et al.</i> , "In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor," <i>Circulation</i> 88:I-476, Abstract No. 2565, American Heart Association (October 1993)	
	NPL59	Takeshita, S., <i>et al.</i> , "Therapeutic Angiogenesis. A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <i>J. Clin. Invest.</i> 93:662-670, The American Society for Clinical Investigation, Inc. (February 1994)	
	NPL60	Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153, BioMed Central Ltd. (February 2001)	
	NPL61	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," <i>Am. J. Med. Sci.</i> 306:129-136, Lippincott Williams & Wilkins (August 1993)	

Examiner Signature		Date Considered	4.4.06
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			Application Number	09/935,726
			Filing Date	August 24, 2001
			First Named Inventor	Hu, Jing-Shan
			Art Unit	1647
			Examiner Name	Landsman, Robert S.
			Attorney Docket Number	1488.100000O/HCC/LMB
Sheet	4	of	4	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
PL	NPL62	Witzenbichler, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>Am. J. Pathol.</i> 153:381-394, American Society for Investigative Pathology, Inc. (August 1998)	
	NPL63	Yeung, P.K.F., "VEGF-2," <i>Curr. Opin. Invest. Drugs</i> 2:796-800, PharmaPress Ltd. (June 2001)	
	NPL64	Litwin, M.S., <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," in <i>Human Cytokines: Their Role in Disease and Therapy</i> , Aggarwal, B.B. and Puri, R.K., eds., Blackwell Science, Boston, Chapter 7, pp 101-129 (January 1995)	
	NPL65	Walsh, C.E., <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>Proc. Soc. Exp. Biol. Med.</i> 204:289-300, Society for Experimental Biology and Medicine (December 1993)	
	NPL66	Anderson, W.F., "Human gene therapy," <i>Nature</i> 392:25-30, Macmillan Magazines Ltd. (April 1998)	
	NPL67	Maynard, J. and Georgiou, G., "Antibody Engineering," <i>Annu. Rev. Biomed. Eng.</i> 2:339-376, Annual Reviews (August 2000)	
	NPL68	Morea, V., <i>et al.</i> , "Antibody Modeling: Implications for Engineering and Design," <i>Methods</i> 20:267-279, Academic Press (March 2000)	


504216\_1.DOC

Examiner Signature		Date Considered	4.4.06
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08a/b (05-03)  
Approved for use through 05/31/2003. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/935,726-Conf. #3533		
		Filing Date	August 24, 2001		
		First Named Inventor	Jing-Shan Hu		
		Art Unit	1647		
		Examiner Name	R. Landsman		
Sheet	1	of	2	Attorney Docket Number	PF112P3D1C

RECEIVED

JUN 23 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PL	FR	Statutory Declaration of Kari Alitalo, executed on August 14, 2002, and accompanying Exhibits KA-1 and KA-2	
	FS	Statutory Declaration of Peter Adrian Walton Rogers, executed on August 9, 2002	
	FT	Statutory Declaration of Francis John Ballard, executed on July 16, 2002	
	FU	Statutory Declaration of Kari Alitalo, executed on July 16, 2002, and accompanying Exhibit 1.	
	FV	Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I to IV	
	FW	Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002	
	FX	Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I to III	
	FY	Statutory Declaration of Gary Baxter Cox, executed on March 22, 2002, and accompanying Exhibit GBC24 (Statutory Declaration of Peter Adrian Walters, executed on October 26, 2001)	
	FZ	Statutory Declaration of Frances John Ballard, executed on December 12, 2001, and accompanying Exhibit 1	
	GA	Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and accompanying Exhibits 1 and 2	
	GB	Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and accompanying Exhibits PAWR1 to PAWR14	
	GC	Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and accompanying Exhibits JSM1 to JSM4	
	GD	Statutory Declaration of Nicholas Kim Hayward, executed on December 8, 2000, and accompanying Exhibits NKH 1 and 2	

Examiner Signature	<i>Carroll</i>	Date Considered	4-10-06
-----------------------	----------------	--------------------	---------



PTO/SB/08a/b (05-03)  
Approved for use through 05/31/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/935,726-Conf. #3533	
			Filing Date	August 24, 2001	
			First Named Inventor	Jing-Shan Hu	
			Art Unit	1647	
			Examiner Name	R. Landsman	
Sheet	2	of	2	Attorney Docket Number	PF112P3D1C1

NON PATENT LITERATURE DOCUMENTS			
GE	Statutory Declaration of Jennifer Ruth Gamble, executed on December 12, 2000, and accompany Exhibits JRG 1 to 3		
GF	Statutory Declaration of Tom Rapoport, executed on December 13, 2000, and accompanying Exhibits TP 1 and 2		
GG	Statutory Declaration of Stuart A. Aaronson, executed on December 14, 2000, and accompanying CV		
GH	Statutory Declaration of Susan Power, executed on December 13, 2000, and accompanying Appendices 1 to 2 and F161		
GI	Statutory Declaration of Gary Baxter Cox, executed on December 13, 2000, and accompanying Exhibits GBC 1 to 23		
GJ	Statutory Declaration of Peter Adrian Walton Rogers, executed on February 16, 2000, and accompanying Exhibit 1		
GK	Statutory Declaration of Frances John Ballard, executed on February 16, 2000, and accompanying Exhibit 1		
GL	Statutory Declaration of Kari Alitalo, executed on February 15, 2000, and accompanying Exhibits 1 to 3		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

RECEIVED  
JUN 23 2003  
TECH CENTER 1600/2900

Examiner Signature		Date Considered	4. 10. 06
-----------------------	--	--------------------	-----------